Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam for Sedated Hysteroscopy in Overweight or Obese Patients
NCT06004843Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Aug 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of remimazolam (2 arms), sponsored by Renji Hospital. Primary endpoint: The incidence of hypoxia. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
remimazolam
Beyond the preview
Go deeper on NCT06004843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004843.